The fibro-adipogenic progenitor APOD+DCN+LUM+ cell population in aggressive carcinomas

During carcinoma progression, mesenchymal stromal cells become recruited to tumors and contribute to the pool of CAFs. The heterogeneity of CAF populations, changing during disease progression, has been recognized [1]. CAFs can be derived from tissue-resident fibroblasts as well as various other lineages. However, CAF sub-populations are diverse and have incompletely understood effects on disease progression and resistance to therapy. Here, by analyzing public databases of human single-cell RNAseq (scRNA-seq) data, we have identified a CAF progenitor population marked by expression of genes APOD, DCN, LUM, typically accompanied by expression of CFD, CXCL14, PTGDS, MGP, SERPINF1, and DPT. We show that these cells are prominent in the following two settings:

The ASC/FAP progenitor population has both adipogenic and fibroblastic differentiation potential. In this work, we provide evidence that it is recruited by cancer cells and undergoes differentiation into CAFs (Fig. 1a).

The ASC/FAP signature reflects remarkably similar lists of marker genes in the ASC cluster [2] (Fig. 1b) and the FAP cluster [3] (Fig. 1c). The presence of the same signature in both ASCs and FAPs is also consistent with the finding that adipose tissue is a source of FAP-like cells recruited to skeletal muscle undergoing remodeling [4]. To demonstrate that the ASC/FAP population exists in abundance in each of the 25 adipose tissue samples presented previously [2], we analyzed each of those samples derived from 14 cancer-free individuals. We used an attractor algorithm [5] (Methods in Supplementary Information) designed to converge to a ranked list of genes identifying the core co-expression characterizing cell populations. We independently generated the lists of top-ranked genes for each sample. Supplementary Table 1 shows that all genes mentioned above are consistently top ranked, while Supplementary Fig. 1 demonstrates the abundance of the ASC/FAP population in the SVF.

We identified similarly enriched ASC/FAP genes in cell clusters of bladder [6], ovarian [7], and breast [8] cancer (Fig. 1d). The twelve top differentially expressed genes (DEGs) of a population were also found to have a three-fold enrichment in chemo-resistant samples of pancreatic cancer, referred to as constituting a “chemo-resistance signature” as shown in their extended data Fig. 7b (Fig.1e) [9]. The strong enrichment of the ASC/FAP cell population in multiple cancer types is consistent with the recruitment of this particular progenitor population in aggressive and chemo-resistant cancers. Consistently, lineage tracing and transplantation studies in mouse models indicate that ASCs can be recruited by carcinomas to promote cancer progression [10, 11].

The recruited ASC/FAP cells are typically misrepresented as inflammatory CAFs (“iCAFs”) because they are often included in nonhomogeneous computationally derived clusters that also contain such cells. iCAFs have been defined as fibroblasts expressing IL6 and additional inflammatory mediators [12], and the expression of IL6 has remained a requirement in a Consensus Statement of experts describing iCAFs [13]. IL6 expression can also be induced in a subset of cells in such clusters. However, the ASC/FAP population in its original non-inflammatory status should not be confused with IL6+ iCAFs. For example, the three representative genes for each fibroblastic subpopulation in Fig. 5D of Dominguez et al. [14] are shown in Fig. 1f. Cluster 1 is marked by genes C7, CFD and PTGDS, all three of which are among the twelve in the chemo-resistance ASC/FAP signature in Fig. 1e. Cluster 2 is marked by IL6, HAS1 and CCL2, all among the iCAF signature genes defined previously [15], hence identifying it as the true iCAF population. It was recently suggested that there are “two separate populations of iCAFs: one IL6 positive and another IL6 negative.” [16] In fact, the IL6-negative cluster largely contains the APOD+ ASC/FAP population and should not be characterized as iCAFs.

Single-cell analysis revealed that, in aggressive cancers, cells with the ASC/FAP signature convert to a particular type of CAFs expressing COL11A1, THBS2, and INHBA [17]. This CAF signature was first reported by Kim et al. [18] and included additional genes such as POSTN, COL10A1, and MMP11. One example consistent with the transition is described by Fig. 2a of Wang et al. [19], in which cluster C0 expresses APOD, DCN, and LUM, while cluster C3 adjacent to it expresses COL11A1, THBS2, and INHBA (Fig. 1g). Furthermore, the presence of the COL11A1+ cluster 0, adjacent to C7+CFD+PTGDS+ cluster 1 in Fig. 5D from Dominguez et al., [14] is also consistent with the transition, as is the presence of gene POSTN together with APOD, CFD, and CXCL14 in the same “poor prognosis” cluster (CAF_0) [20] in gastric cancer. COL11A1 is also identified as the collagen marker most strongly associated with poor prognosis [16].

In summary, this commentary draws attention to the APOD+DCN+LUM+ gene signature as representing an important unrecognized population in cancer. These cells are likely derived from ASC/FAPs recruited by carcinomas; however, their origination from other sources cannot be excluded. Their differentiation into COL11A1+ CAFs, accompanying the transition to metastasis, may underlie a mechanism that accounts for the role of adipose tissue in cancer aggressiveness [21]. Genetic manipulations of ASCs in cell culture and animal models of carcinoma progression to chemo-resistance will be necessary to obtain further evidence for the origin of CAFs associated with poor prognosis of cancer. Further research may help in developing appropriate therapeutics targeting the underlying mechanisms.